Metagenomi (NASDAQ:MGX) Given New $15.00 Price Target at Chardan Capital

Metagenomi (NASDAQ:MGX) had its target price trimmed by Chardan Capital from $17.00 to $15.00 in a research report released on Monday, Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms have also recently issued reports on MGX. HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of Metagenomi in a research note on Monday, July 15th. JPMorgan Chase & Co. downgraded shares of Metagenomi from an overweight rating to a neutral rating and dropped their price target for the stock from $16.00 to $6.00 in a research report on Thursday, May 2nd. Finally, BMO Capital Markets decreased their price objective on shares of Metagenomi from $22.00 to $17.00 and set an outperform rating for the company in a report on Thursday, August 15th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $16.00.

Metagenomi Trading Up 11.7 %

MGX stock opened at $3.15 on Monday. Metagenomi has a 1 year low of $2.76 and a 1 year high of $12.74. The company has a fifty day moving average of $4.17.

Institutional Trading of Metagenomi

A number of hedge funds and other institutional investors have recently made changes to their positions in MGX. Resolute Advisors LLC acquired a new position in Metagenomi in the first quarter worth approximately $106,000. Vanguard Group Inc. acquired a new stake in shares of Metagenomi during the first quarter worth approximately $1,894,000. Altitude Crest Partners Inc. acquired a new stake in Metagenomi during the first quarter valued at $1,407,000. Hhlr Advisors LTD. bought a new position in shares of Metagenomi during the 1st quarter valued at $8,205,000. Finally, Artal Group S.A. bought a new position in shares of Metagenomi in the 1st quarter valued at approximately $3,165,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.